ArticleCancer drug resistance (Alhambra, Calif.)2019

Resistance to ERK1/2 pathway inhibitors; sweet spots, fitness deficits and drug addiction.

Matthew J Sale et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.